Inflammatory biomarker outcomes associated with MDMA-assisted therapy: an open-label exploratory study

Area of Science:

• Neuroscience
• Psychiatry
• Immunology

Background:

• Posttraumatic stress disorder (PTSD) is linked to increased inflammation and chronic illness risk.
• Few studies have investigated the impact of PTSD interventions on inflammatory biomarkers.
• 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy shows promise for rapid PTSD symptom reduction.

Purpose of the Study:

• To examine within-person changes in inflammatory biomarkers during MDMA-assisted group therapy for Veterans with PTSD.
• To explore the relationship between inflammatory biomarkers and PTSD symptom severity.
• To investigate potential biomarker-symptom correlations in the context of MDMA-assisted therapy.

Main Methods:

• Collected blood plasma samples from 23 Veterans at baseline and end-of-intervention.
• Calculated effect sizes for interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and C-reactive protein (CRP).
• Assessed PTSD severity using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and analyzed correlations between biomarkers and symptoms.

Main Results:

• Observed small increases in IL-6 and CRP, and a small decrease in TNF-α.
• Found positive associations between baseline IL-6, TNF-α, and PTSD severity (CAPS-5 scores).
• Higher baseline IL-6 weakly predicted symptom improvement, and IL-6 changes correlated with symptom changes.

Conclusions:

• MDMA-assisted therapy may modulate inflammatory biomarkers in Veterans with PTSD.
• Results highlight potential relationships between specific biomarkers and PTSD symptom severity.
• These preliminary findings warrant further investigation in larger studies.